Search Results

You are looking at 161 - 170 of 388 items for :

  • Refine by Access: All x
Clear All
Full access

Integrating Palliative Care Into Comprehensive Cancer Care

Janet L. Abrahm

equated the nausea and vomiting the drugs caused with their effectiveness. Those who gave cisplatin before 5-HT3RI and NK-1 inhibitors were available, using metoclopramide at 100 mg/m 2 every 2 hours for 6 cycles (along with lorazepam and diphenhydramine

Full access

New Persistent Opioid and Benzodiazepine Use After Curative-Intent Treatment in Patients With Breast Cancer

Mandy R. Sakamoto, Megan Eguchi, Christine M. Azelby, Jennifer R. Diamond, Christine M. Fisher, Virginia F. Borges, Cathy J. Bradley, and Peter Kabos

prescribed adjunct to antiemetic drugs for chemotherapy-related nausea. 18 Few studies have evaluated short- and long-term opioid use in patients with breast cancer and are limited to single treatment modalities or descriptive statistics. Dispensing patterns

Full access

Functional Impairment, Symptom Burden, and Clinical Outcomes Among Hospitalized Patients With Advanced Cancer

Daniel E. Lage, Areej El-Jawahri, Charn-Xin Fuh, Richard A. Newcomb, Vicki A. Jackson, David P. Ryan, Joseph A. Greer, Jennifer S. Temel, and Ryan D. Nipp

symptoms, respectively. Both measures are widely used in the oncology setting and considered to be valid and reliable. The self-administered ESAS-r was used to assess patients’ physical symptoms, including nausea, dyspnea, lack of appetite, pain, drowsiness

Full access

Combination Therapy of Physical Activity and Dexamethasone for Cancer-Related Fatigue: A Phase II Randomized Double-Blind Controlled Trial

Sriram Yennurajalingam, Vicente Valero, Zhanni Lu, Diane D. Liu, Naifa L. Busaidy, James M. Reuben, Carolina Diaz Fleming, Janet L. Williams, Kenneth R. Hess, Karen Basen-Engquist, and Eduardo Bruera

used to assess 10 symptoms commonly experienced by patients with cancer during the previous 24 hours: pain, fatigue, nausea, depression, anxiety, drowsiness, dyspnea, anorexia, sleep, and feelings of well-being. 13 , 16 , 21 , 22 For the purpose of

Full access

Outcomes From a Patient-Centered, Interprofessional, Palliative Consult Team in Oncology

Andrea Feldstain, Barry D. Bultz, Janet de Groot, Amane Abdul-Razzak, Leonie Herx, Lyle Galloway, Srini Chary, and Aynharan Sinnarajah

quarterly over 2 years). Referrals were from oncology or palliative care clinicians for patients experiencing complex cancer symptoms, including physical symptoms (pain, nausea) or psychosocial-spiritual concerns (depression, anxiety, illness adjustment

Full access

NCCN Guidelines® Insights: Palliative Care, Version 2.2021

Featured Updates to the NCCN Guidelines

Maria Dans, Jean S. Kutner, Rajiv Agarwal, Justin N. Baker, Jessica R. Bauman, Anna C. Beck, Toby C. Campbell, Elise C. Carey, Amy A. Case, Shalini Dalal, Danielle J. Doberman, Andrew S. Epstein, Leslie Fecher, Joshua Jones, Jennifer Kapo, Richard T. Lee, Elizabeth T. Loggers, Susan McCammon, William Mitchell, Adeboye B. Ogunseitan, Diane G. Portman, Kavitha Ramchandran, Linda Sutton, Jennifer Temel, Melissa L. Teply, Stephanie Y. Terauchi, Jane Thomas, Anne M. Walling, Finly Zachariah, Mary Anne Bergman, Ndiya Ogba, and Mallory Campbell

(pain, nausea, anxiety, depression, shortness of breath, drowsiness, well-being, loss of appetite, and tiredness) in the last weeks of life. 4 Several groups, including the WHO, ASCO, and American Society of Hematology, recommend integrating

Full access

Clinical Outcomes With Abemaciclib After Prior CDK4/6 Inhibitor Progression in Breast Cancer: A Multicenter Experience

Seth A. Wander, Hyo S. Han, Mark L. Zangardi, Andrzej Niemierko, Veronica Mariotti, Leslie S.L. Kim, Jing Xi, Apurva Pandey, Siobhan Dunne, Azadeh Nasrazadani, Avinash Kambadakone, Casey Stein, Maxwell R. Lloyd, Megan Yuen, Laura M. Spring, Dejan Juric, Irene Kuter, Ioannis Sanidas, Beverly Moy, Therese Mulvey, Neelima Vidula, Nicholas J. Dyson, Leif W. Ellisen, Steven Isakoff, Nikhil Wagle, Adam Brufsky, Kevin Kalinsky, Cynthia X. Ma, Joyce O’Shaughnessy, and Aditya Bardia

specific event of interest (via the CTCAE version 4.03) was noted if multiple episodes of an adverse effect occurred during the treatment course. Subjective adverse effects, including diarrhea, fatigue, and nausea, were not graded as part of this

Full access

Identification and Characterization of Avoidable Hospital Admissions in Patients With Lung Cancer

Eric M. Lander, Xuanyi Li, Li-Ching Huang, Amanda S. Cass, Wade T. Iams, Emily A. Skotte, Jennifer G. Whisenant, Robert A. Ramirez, Sally J. York, Travis J. Osterman, Jennifer A. Lewis, Christine M. Lovly, Yu Shyr, and Leora Horn

hospitalization included cancer-related pain (n=40; 13%), acute hypoxemic respiratory failure (n=39; 12%), failure to thrive (n=39; 12%), altered mental status (n=23; 7%), and nausea or vomiting (n=22; 7%). Based on a multidisciplinary 2-stage review process, 47

Full access

Health-Related Quality of Life in Patients With Metastatic Colorectal Cancer Undergoing Systemic Therapy With or Without Maximal Tumor Debulking

Lotte Bakkerus, Laurien M. Buffart, Tineke E. Buffart, Yannick M. Meyer, Barbara M. Zonderhuis, Cornelis J.A. Haasbeek, Kathelijn S. Versteeg, Olaf J.L. Loosveld, Jan Willem B. de Groot, Mathijs P. Hendriks, Cornelis Verhoef, Hendrik M.W. Verheul, and Elske C. Gootjes

investigated using the EORTC Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). 29 , 30 This questionnaire consists of 5 functional scales (physical, social, role, cognitive, and emotional functioning), 3 symptom scales (fatigue, pain, and nausea

Full access

Resurrection of PARP Inhibitors in Breast Cancer

Tomas G. Lyons and Mark E. Robson

survival between the 2 groups. No new safety signals were observed. Any-grade nausea and vomiting were increased with olaparib compared with standard chemotherapy (58% vs 35.2%, respectively, and 29.8% vs 15.4%, respectively). Olaparib was associated with